RT Journal Article
SR Electronic
T1 A Multicenter Study of Coronavirus Disease 2019 Outcomes of Cancer Patients in Wuhan, China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.21.20037127
DO 10.1101/2020.03.21.20037127
A1 Hongyan Zhang
A1 Linwei Wang
A1 Yuanyuan Chen
A1 Xiaokun Shen
A1 Qun Wang
A1 Youqin Yan
A1 Yi Yu
A1 Qiuji Wu
A1 Yahua Zhong
A1 Melvin L.K. Chua
A1 Conghua Xie
YR 2020
UL http://medrxiv.org/content/early/2020/04/15/2020.03.21.20037127.abstract
AB Background At present, there is a global pandemic of coronavirus disease 2019 (COVID-19) pneumonia. For COVID-19 patients, cancer is a coexisting disease that should not be Here, we conducted a multicenter retrospective study to show the clinical information and outcomes of cancer patients infected with COVID-19.Measurements Medical records of COVID-19 patients with cancer admitted to hospitals from Jan 5, 2020 to Feb 18, 2020 were collected.Results Of the 67 patients (median age: 66 years), the median age of patients with severe illness was older than that of patients with mild symptoms (P<0.001). The proportion of severe patients had co-morbidities was higher than patients with mild disease (P=0.004). During the treatment of COVID-19 pneumonia, tumor progression and recurrence was not observed for those patients still at the anticancer treatment phase. Lymphocytopenia was the main laboratory finding accompanying increased C-reactive protein and procalcitonin in cancer patients, especially in severe cases. By Mar 10, 2020, 18 (26.9%) patients died from COVID-19. The median age of survivors was younger than that of deaths (P=0.014). Lung cancer (n=15, 22.4%) was the most common cancer type and accounted for the highest proportion COVID-19 resulted deaths (33.3%, 5/15). We observed a tendency that patients at the follow-up phase had a better prognosis than that at anticancer treatment phase (P=0.095).Conclusion This study showed COVID-19 patients with cancer seem to have a higher proportion of severe cases and poorer prognosis. We should pay more intensive attentions to cancer patients infected with COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot availableFunding StatementPrimary Funding Source: This study was funded by Health Commission of Hubei Province Scientific Research Project (WJ2019H002) and Health Commission of Hubei Province Medical Leading Talent Project, and National Key Research and Development Program of China (2020YFC0845500). Role of the Funder/Sponsor The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data of this study is available to all authorized members.